National Conference: Regular Registration Ending Soon

Regular registration rates for attendees for the 19th Annual National Patient Education Conference in Chandler, Ariz., end on Monday, June 26. Register soon to take advantage of reduced rates.

Read more and register for the conference.

Don't miss news about this year's conference in Arizona. Sign-up for eAlerts today!

Recently, the results of two studies presented at the annual European Congress of Rheumatology (EULAR) suggested that two new tools may play a pivotal role in the early diagnosis of scleroderma.

Read more

Last month, the United States House of Representatives passed the American Health Care Act (AHCA) which included billions of dollars of funding cuts to your state's Medicaid program. The U.S. Senate currently is considering passing the same or similar legislation, and it is up to us to ensure that the Senate does not enact these harmful cuts. 

Medicaid provides a lifeline to some of our most vulnerable citizens, individuals with rare diseases, and these cuts could be devastating. Medically necessary prescription drugs and medical care could go uncovered, and patients could be denied coverage altogether.

Learn more about how you can help from the National Organization for Rare Diseases (NORD) through their "Days of Action to Protect Your Coverage" and contact your Senator now.

Take action

As we wrap-up Scleroderma Awareness month, there are just a few more days to capitalize on efforts to get the word out about scleroderma.  All month, the Scleroderma Foundation has worked alongside Scleroderma Canada and the Scleroderma Research Foundation to raise awareness of our devastating disease.

The “Hard Word. Harder Disease.” campaign has been an effective knowledge building tool. Last year alone the campaign served over 5 million impressions on people you know, and people your friend’s friend knows.  With your help, this year’s campaign has continued to make scleroderma known.

In this last week of the campaign, take time to share the message one more time. If you have not already done so, go to www.HardWord.org and take the pledge to tell others about scleroderma. If you have already pledged, direct your friends and family to the site and share the stories, and make others more aware through your personal and social media network.

Thanks for adding your voice to scleroderma awareness.

Living with a rare disease can be isolating, but know you aren’t alone! Join the Pulmonary Hypertension Association on the Road and connect with people who understand what it’s like living with a rare disease, speak with local PH expert.

PHA on the Road is a FREE day-long education and networking program for patients and caregivers – that includes complimentary meals, childcare and valet parking.

Register today!

As part of Scleroderma Awareness Month, join New York's Hospital for Special Surgery at 1:30 p.m. eastern Monday, June 26, for a Facebook Live broadcast with a patient and Dr. Robert Spiera, the Director of our Scleroderma, Vasculitis, & Myositis Center. Have a question about scleroderma you'd like them to address? Comment on their Facebook page now.

Clinical Trials

Corbus Pharmaceuticals Phase 2 Study Data

Corbus Pharmaceuticals recently issued a statement announcing that safety and efficacy data from its previously completed Phase 2 clinical study of anabasum (formerly known as JBT-101) for the treatment of diffuse cutaneous systemic sclerosis, which was presented at the European League Against Rheumatism (“EULAR”) Annual Meeting in Spain.

Dr. Robert Spiera presented the abstract titled, “A Phase 2 study safety and efficacy of anabasum (JBT-101) in systemic sclerosis.” He is the Director of the Vasculitis and Scleroderma Program at the Hospital for Special Surgery, Weill Cornell Medical College in New York City, and Principle Investigator of Corbus' Phase 2 systemic sclerosis clinical study. View the presentation.